Plain-English translation of NCT05718492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a treatment called hepatic arterial infusion chemotherapy (HAIC), which delivers cancer-fighting drugs directly to the liver through a thin tube called a catheter. You would receive this treatment if your liver cancer has advanced and has not responded well to previous immunotherapy or anti-angiogenic drugs. The goal is to see whether this targeted delivery method can help control your cancer more effectively.
Many patients with advanced liver cancer stop responding to standard immunotherapy and anti-angiogenic treatments, and doctors need better options for these patients. This trial is testing whether delivering chemotherapy directly to the liver—rather than throughout the whole body—might work better and cause fewer side effects.
You likely qualify if…
You likely don't qualify if…
You would receive a procedure to place a thin catheter (tube) into the artery that feeds your liver, guided by special imaging. Then, over 3-week cycles, chemotherapy drugs would be infused directly through this catheter into your liver. You would typically receive 4 to 6 cycles of treatment. If your cancer has spread outside the liver, you may also receive immunotherapy as an additional treatment. You'll need to visit the hospital regularly for these infusions and blood tests to monitor your health and how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China